Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Samoa Wellness Report.
Press releases published on August 19, 2025
Global Central Lab Services Market to Reach USD 8.18 Billion by 2030 | MarketsandMarkets™
GlobeNewswire
·
August 19, 2025
Delray Beach, FL, Aug. 19, 2025 (GLOBE NEWSWIRE) -- The global Central Lab Services Market, valued at US$5.64 billion in 2024, stood at US$5.97 billion in 2025 and is projected to advance at a resilient CAGR of 6.5% from 2025 to 2030, culminating in a …
Aveanna to Participate at the Deutsche Bank Healthcare Summit
GlobeNewswire
·
August 19, 2025
ATLANTA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the Deutsche Bank Healthcare Summit in New York on September 10, 2025. Management will host 1x1 …
Global Negative Pressure Wound Therapy Market to Surpass USD 3.84 Billion by 2030 | MarketsandMarkets™
GlobeNewswire
·
August 19, 2025
Delray Beach, FL, Aug. 19, 2025 (GLOBE NEWSWIRE) -- The global negative pressure wound therapy market, valued at US$2.59 billion in 2024, stood at US$2.76 billion in 2025 and is projected to advance at a resilient CAGR of 6.9% from 2025 to 2030, …
Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)
GlobeNewswire
·
August 19, 2025
Pemvidutide is the only drug currently granted Fast Track Designation in AUD RECLAIM, a Phase 2 trial of pemvidutide in AUD, is currently enrolling GAITHERSBURG, Md., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage …
OptimizeRx Corporation Announces Leadership Team Advancements to Accelerate Strategic Growth
GlobeNewswire
·
August 19, 2025
WALTHAM, Mass., Aug. 19, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today …
Angitia Biopharmaceuticals to Present Data on AGA2115 for Osteogenesis Imperfecta at ASBMR 2025
GlobeNewswire
·
August 19, 2025
- Angitia abstracts selected for two oral presentations and three posters - Angitia collaborator also selected for poster presentation WESTLAKE VILLAGE, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Angitia Biopharmaceuticals, a clinical-stage biotechnology …
Memo Therapeutics AG Publishes Phase I Safety, Tolerability, and Pharmacokinetics Study for Neutralizing Antibody Targeting BKPyV Infection in Clinical and Translational Science
GlobeNewswire
·
August 19, 2025
First-in-human, Phase I, randomized, placebo-controlled study, successfully demonstrated safety and tolerability of potravitug in healthy volunteers The Company recently announced the results from its Phase II placebo-controlled clinical trial of …
BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
GlobeNewswire
·
August 19, 2025
Data from more than 2,600 agitation episodes collected Topline data readout is on track for August NEW HAVEN, Conn., Aug. 19, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial …
Teleflex Announces the Launch of Barrigel™ Rectal Spacer in Japan as a Proven Safe and Effective Option to Minimize the Harmful Long-Term Side Effects of Prostate Radiation Therapy
GlobeNewswire
·
August 19, 2025
Innovative hyaluronic acid technology delivers enhanced control and precision, significantly lowering the risk of rectal toxicity during prostate radiation treatment.1-4 Initial cases have now been performed in Japan. WAYNE, Pa., Aug. 19, 2025 (GLOBE …
Merakris Therapeutics Receives USPTO Notice of Allowance for Foundational Patent Supporting MTX-001 Biologic Drug Platform
GlobeNewswire
·
August 19, 2025
RESEARCH TRIANGLE PARK, N.C., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics today announced the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent No. US-2022/0133806 A1, covering the company's …
Zymeworks Announces Participation in Upcoming Investor Conferences
GlobeNewswire
·
August 19, 2025
VANCOUVER, British Columbia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to- …
Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team
GlobeNewswire
·
August 19, 2025
STAFFORD, Texas, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy …
ITM to Present New Subgroup Analysis Data from the COMPETE Trial at ESMO 2025 and Host an Educational Event for Healthcare Professionals
GlobeNewswire
·
August 19, 2025
Garching / Munich, Germany, August 19, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that further data on efficacy, safety and subgroup analysis from its recent Phase 3 COMPETE trial will be …
Scientists Discuss the Recent CancerVax Breakthrough
GlobeNewswire
·
August 19, 2025
Lehi, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Lehi, Utah, August 19, 2025 – CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform designed to use the body’s immune system to treat cancer, today announced the release of a video …
Basilea mit starkem Halbjahresergebnis 2025 auf Kurs
GlobeNewswire
·
August 19, 2025
Cresemba- und Zevtera-basierte Umsätze steigen um 24 % auf CHF 90.5 Mio. Gesamtumsatz steigt signifikant um 36 % auf CHF 104.0 Mio. Betriebsgewinn springt um 160 % auf CHF 24.0 Mio. Operativer Cashflow erhöht sich um 29 % auf CHF 23.1 Mio. Guidance für das …
Basilea on track with strong 2025 half-year results
GlobeNewswire
·
August 19, 2025
Cresemba® and Zevtera®-related revenues rise by 24% to CHF 90.5 million Total revenue grows significantly by 36% to CHF 104.0 million Operating profit surges by 160% to CHF 24.0 million Operating cash flow increases by 29% to CHF 23.1 million Full-year …
Santhera schließt Vereinbarung mit Uniphar über den Vertrieb von AGAMREE® (Vamorolon) in fünf Ländern des Golf-Kooperationsrats (GCC)
GlobeNewswire
·
August 19, 2025
Pratteln, Schweiz, 19. August 2025 – Santhera Pharmaceuticals (SIX: SANN) gibt die Unterzeichnung einer exklusiven Vereinbarung mit Uniphar über den Vertrieb von AGAMREE® (Vamorolon) in den Vereinigten Arabischen Emiraten, Saudi-Arabien, Kuwait, Oman und …
Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® (Vamorolone) in five GCC (Gulf Cooperation Council) Countries
GlobeNewswire
·
August 19, 2025
Pratteln, Switzerland, 19 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® (vamorolone) in the United Arab Emirates, the Kingdom of Saudi Arabia, Kuwait, …
argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025
GlobeNewswire
·
August 19, 2025
August 19, 2025 Amsterdam, the Netherlands – argenx (Euronext …
CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program
GlobeNewswire
·
August 19, 2025
SINGAPORE, Aug. 18, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood- …